HCA Healthcare

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:HCA) with a Equal-Weight and lowers the price target from $267 to $254.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target $34 to $270, reflecting a 2024 P/E of 13.3x vs. three- and five-year averages of 12.8x and 12.2x, respectively. We raise our 2023 adj. EPS view by $0.18 to $18.36 and raise 2024’s by $0.35 to $20.28. Q3 adj. EPS of $3.91 vs. $3.91 missed consensus by $0.06. The adj. EBITDA margin fell to 17.8% from 19.4% in Q3 2022, negatively impacted by weaker results from its Valesco joint venture, which the company expects will continue posing headwinds in the coming quarters. Accordingly, HCA’s 2023 adj. EBITDA margin guidance midpoint dropped to 19.45% from 19.60%. We think this somewhat overshadowed what was otherwise a strong quarter in terms of underlying hospital volume growth and containment of inflationary wage costs. On a same-facility

HCA Healthcare Sees FY Rev $63.25B-$64.75B.

HCA Healthcare Reports Third Quarter 2023 Results Revises 2023 Guidance NASHVILLE, Tenn.–October 24, 2023– HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2023. Key third quarter metrics (all percentage changes compare 3Q 2023 to 3Q 2022 unless otherwise noted): — Revenues totaled $16.213 billion — Net income attributable to HCA Healthcare, Inc. totaled $1.079 billion, or $3.91 per diluted share — Adjusted EBITDA totaled $2.880 billion — Cash flows from operating activities totaled $2.479 billion — Same facility admissions increased 3.4 percent while same facility equivalent admissions increased 4.1 percent “During the quarter, most aspects of our business were positive, including continued solid demand for our services, which translated into strong revenue growth. However, our results were unfavorably impacted by our Valesco physician staffing joint venture, which performed below our expectations,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.